Sublingual Ketamine in the Aesthetic Suite: Where It Fits, and What It Costs You

Sublingual ketamine has become a standing question in aesthetic practice, and it deserves a careful answer rather than an enthusiastic one. It is a genuinely effective analgesic and anxiolytic, I use ketamine routinely in anesthesia and pain practice, and there is a narrow set of aesthetic procedures where it is the pharmacologically correct choice. It is also the single highest-burden, highest-regulatory-exposure item anywhere in a comfort plan, and the operational cost of having it in the building is much larger than the cost of the drug.

Before anything else, the boundary that governs this entire article.

This piece is written for licensed prescribers with controlled-substance authority, and it contains no doses. Whether ketamine may be prescribed or administered at all, by whom, in what setting, with what monitoring, and under what sedation permit is determined by your professional licence, your state's practice act, your state's controlled-substance law and — where applicable — your facility's accreditation. Those rules vary enormously between states and between licence types, far more than most of the other material in this cluster. Nothing here authorises anything. Before any practice adopts this, the decision belongs in front of your own counsel and your malpractice carrier, not in front of a blog post.

Where it fits, and where it emphatically does not

Start with the clinical judgement, because it is the part that is easiest to get wrong in both directions.

Ketamine is the wrong tool for neurotoxin. A toxin appointment is a handful of small-gauge injections over a few minutes. The discomfort is brief, superficial and well controlled by the non-pharmacologic tier — ice, chilled air, vibration, firm counter-pressure — with topical anesthetic if you want it. Reaching for a dissociative anesthetic for a fifteen-minute toxin appointment is a pharmacologic response wildly out of proportion to the stimulus, and it converts a simple, low-risk, walk-in-walk-out service into a controlled-substance encounter with a monitoring obligation and a transport requirement. That is not a trade any practice should make. The comfort plan for the work taught in Complete Botox Training belongs firmly on the bottom rung of the ladder.

Where it makes pharmacologic sense is the opposite kind of appointment: sustained, higher-intensity discomfort over a long session. The three procedures that come up repeatedly are radiofrequency microneedling — not plain microneedling, which is a different order of stimulus — intense laser treatments, and PDO thread lifting. What these share is duration plus a depth of tissue injury that topical anesthetic does not reach and that a field block only partially covers. Those are also, not coincidentally, the procedures where an anxious patient is most likely to abandon a treatment plan after one session.

So the indication logic is sound. The rest of this article is about what accepting that indication actually obliges you to do.

The pharmacology, stated properly

Ketamine is an NMDA receptor antagonist. At anesthetic doses it produces a dissociative state — the patient appears disconnected from their environment rather than simply asleep. At sub-anesthetic doses it produces analgesia and anxiolysis with preserved airway reflexes and preserved respiratory drive, which is precisely why it is attractive outside an operating room.

Three properties distinguish it from every other agent in this cluster.

It is a true analgesic, not merely an anxiolytic. Unlike a benzodiazepine, which reduces the distress of pain without reducing pain, ketamine acts on nociceptive transmission directly. That is the whole reason it is under consideration for procedures that actually hurt.

It is sympathomimetic. Ketamine characteristically raises blood pressure and heart rate. The Ketalar label lists transient increases in blood pressure, heart rate and cardiac index as frequent, and the drug is formally contraindicated in patients for whom a significant elevation of blood pressure would constitute a serious hazard. This is the mirror image of clonidine's problem and it is easy to miss in an aesthetic population that skews toward undiagnosed hypertension.

Airway reflexes are preserved but not protective. The label is explicit that pharyngeal and laryngeal reflexes are not suppressed — and equally explicit that "vomiting and aspiration may occur," and that ketamine "is not recommended for use in patients who have not followed nil per os guidelines." Preserved reflexes are not the same as a protected airway.

Duration. Dr. Thomas-Goering teaches that sublingual preparations give roughly 45 to 60 minutes of effect at typical dosing, which maps well onto the length of the procedures listed above. That figure reflects her clinical practice; it is not a labelled figure, for the reason set out in the next section.

The regulatory reality most discussions skip

Here is the fact that reframes the whole conversation, and it is not a technicality.

There is no FDA-approved oral or sublingual ketamine product. The approved product, Ketalar, is an injection, indicated as a general anesthetic — as the sole anesthetic agent for diagnostic and surgical procedures not requiring skeletal muscle relaxation, for induction of anesthesia, and as a supplement to other anesthetic agents. Its labelled routes are intravenous and intramuscular. Every sublingual "melt," troche, lozenge or rapid-dissolve tablet in circulation is a compounded preparation.

That distinction carries consequences the FDA has stated directly. In an October 2023 compounding risk alert, the agency wrote that compounded drugs "are not FDA approved, which means FDA has not evaluated their safety, effectiveness, or quality prior to marketing," and therefore "do not have any FDA-approved indications or routes of administration." It went on to note that "the dosages of the sublingual and oral compounded ketamine products marketed by compounders and telemedicine platforms may vary, which makes it challenging to predict which potential risks may be associated with these products."

The same alert reported an April 2023 adverse event: a patient who experienced respiratory depression after taking compounded oral ketamine outside a health care setting, with a ketamine blood level that "appeared to be twice the blood level typically obtained for anesthesia."

That case is the single most important thing in this article. The mental model of sublingual ketamine as a gentle, self-limiting oral premedication is not supported. An enteral route does not cap the plasma level — it only makes the level harder to predict, because absorption across the sublingual mucosa versus swallowed drug subject to first-pass metabolism is variable between patients and between preparations.

The FDA alert is directed at psychiatric use, which is not what we are discussing. But the safety and quality findings about the compounded products themselves — variable dosing, unevaluated quality, no established safe dosing, and a documented respiratory depression event — apply to whatever you are using the product for.

What the label says about the setting

The Ketalar label's administration requirements are written for the injectable product, and an aesthetic practice will reasonably argue that a sub-anesthetic sublingual dose is a different proposition. It is. But the label describes the safety architecture the FDA considers appropriate for this molecule, and it is worth reading before deciding how far from it you are comfortable operating:

"KETALAR should be administered by or under the direction of physicians experienced in the administration of general anesthetics, maintenance of a patent airway, and oxygenation and ventilation. Continuously monitor vital signs in patients receiving KETALAR. Emergency airway equipment must be immediately available."

And the patient counselling section:

"Due to the residual anesthetic effects and the potential for drowsiness, advise patients not to drive an automobile, operate hazardous machinery, or engage in hazardous activities within 24 hours of receiving KETALAR."

Twenty-four hours. Not "until you feel steady." If you adopt the labelled counselling standard — and it is difficult to explain why you would not — then ketamine is not a same-day-driving modality by a wide margin, and that changes how the appointment is booked, not just how it is medicated.

Two further label findings matter for a repeat-visit aesthetic population:

• Emergence reactions occur in approximately 12% of patients during recovery, ranging from pleasant dream-like states through vivid imagery and hallucinations to frank emergence delirium, generally lasting a few hours. The label's mitigation is to minimise verbal, tactile and visual stimulation during recovery — which is an awkward fit with a busy treatment floor.
• Recurrent dosing carries organ-specific risk. The label now describes hepatobiliary dysfunction, biliary duct dilatation and stricture, and sclerosing cholangitis with recurrent use, and advises baseline and periodic liver function tests for patients on recurrent ketamine. It also describes serious urologic complications — cystitis, reduced bladder capacity, ureteral stenosis and hydronephrosis — with long-term use. An aesthetic patient on a treatment series is, by definition, a repeat-dosing patient.

The interaction that should stop a stacked plan

This one deserves its own heading because it contradicts an instinct that is common in aesthetics — the instinct to combine.

The Ketalar label states that concomitant use of ketamine with opioid analgesics, benzodiazepines or other CNS depressants, including alcohol, "may result in profound sedation, respiratory depression, coma, and death," and directs close monitoring of neurological status and respiratory parameters including respiratory rate and pulse oximetry.

So the plan that gives an anxious thread-lift patient a benzodiazepine at home and then a sublingual ketamine preparation on arrival is not two mild interventions. It is a combination with a labelled risk of profound sedation and respiratory depression, in a room that very likely has no capnography, no pulse oximeter in continuous use, and nobody whose only job is watching the patient breathe.

Ketamine also lowers the seizure threshold when combined with theophylline or aminophylline, and the label advises considering an alternative in patients on those drugs.

The operational burden, itemised

This is the part that decides it for most practices, and it is worth being concrete rather than gesturing at "it's a controlled substance."

Ketamine is a Schedule III controlled substance under the Controlled Substances Act. Having it in the building means:

• A DEA registration appropriate to the practice and the practitioner, in the correct schedule, at the correct registered address.
• Secure storage meeting controlled-substance requirements, and a physical security plan.
• Perpetual inventory and recordkeeping, with biennial inventory and the disposal documentation that goes with it.
• State controlled-substance registration where your state requires one in addition to the DEA registration, and prescription monitoring program reporting and query obligations, which differ by state.
• A diversion plan. A dissociative Schedule III agent in a practice with staff turnover is a diversion target, and the plan for that is a policy, not a hope.
• Disposal and reverse distribution procedures for expired or unused stock.
• Scope and sedation permitting. Whether you may induce a sedation state at all, at what depth, with what personnel and monitoring, and whether a facility permit or an office-based-surgery registration is triggered, is state law. Some states regulate this tightly; some barely address it; the answer for a nurse practitioner is frequently not the answer for a physician in the same building.
• Malpractice coverage. Carriers do not uniformly cover sedation-adjacent practice in a medical spa setting. This is a phone call to make before the first vial arrives, not after the first incident.

None of that is prohibitive for a practice that genuinely needs the capability. All of it is disproportionate for a practice that wanted a slightly more comfortable filler appointment.

The honest alternatives

Before adopting a Schedule III agent, exhaust the tiers that do not carry one. For the three procedures where ketamine is genuinely indicated, the realistic competing plans are:

• A properly placed field block plus the non-pharmacologic tier. For thread work and for much filler work, this is frequently sufficient, and it is the option most often skipped because the block was never learned properly. The anatomy behind it sits elsewhere in this cluster.
• Inhaled nitrous oxide/oxygen. Non-controlled, self-limiting, rapid on and rapid off — the one modality in this cluster with a serious claim to same-day self-transport, covered in its own article. For long, uncomfortable, non-incisional procedures, this is the alternative that most often makes the ketamine question moot.
• A non-opioid oral analgesic plan, timed properly rather than taken in the car park.
• Splitting the session. Two shorter appointments are sometimes a better answer than one medicated long one, and no regulator has ever objected to it.

What to do on Monday

1. Decide whether the capability is one you actually need, procedure by procedure. If your practice does not routinely perform radiofrequency microneedling, aggressive laser or extensive thread work, the answer is almost certainly no.
2. If the answer is yes, start with your state practice act and your controlled-substance law, not with a compounding pharmacy. Establish who in your building may lawfully prescribe, who may administer, and what sedation depth your setting permits.
3. Call the malpractice carrier before the pharmacy.
4. Build the monitoring plan first. Who watches the patient, with what, for how long after the procedure, and what triggers an escalation. If you cannot staff a dedicated observer, you do not have a plan.
5. Write the discharge and transport rule to the 24-hour counselling standard and put it in the consent document, not in a verbal aside. A practice that already runs disciplined written consent, along the lines of what to include in Botox consent forms, has most of the scaffolding already.
6. Screen for the contraindication that matters most: any patient in whom a significant rise in blood pressure would be hazardous.

The procedures that raise this question are taught hands-on — Advanced PDO Thread Lift Training, Complete Cosmetic Laser Training, and the combination work in Complete Facial Aesthetic Training — and the comfort plan for each is built alongside the technique, not bolted on afterwards. For the higher-volume injectable work in Complete Dermal Filler Training, the answer is nearly always a block rather than a systemic agent.

This assessment reflects Dr. Jennifer Thomas-Goering's clinical practice as taught in Empire Medical Training's hands-on curriculum, cross-checked against the current FDA labelling for KETALAR and the FDA's October 2023 compounding risk alert on compounded ketamine. Prescribing, administration and sedation practice are scope- and state-dependent and are regulated more variably for this agent than for anything else discussed in this cluster. Technique is learned under supervision; this article is educational and is not a substitute for training or for legal advice.

Dr. Jennifer Thomas-Goering, DO, MBA is a board-certified anesthesiologist, clinical lead instructor and executive committee member at Empire Medical Training, and founder of an aesthetics practice in Ann Arbor, Michigan.

Related guides in this cluster

Part of Injectable Anesthesia and Patient Comfort.

Clinical GuideBenzodiazepine or Clonidine? Choosing an Oral Anxiolytic for the Long Aesthetic AppointmentBenzodiazepine vs clonidine for pre-procedure anxiolysis — the mechanisms, the respiratory and scheduling differences, and the screenin Clinical GuideNitrous Oxide in the Aesthetic Practice: Self-Titration, Contraindications and Same-Day DrivingNitrous oxide in aesthetic practice is the one non-controlled, self-limiting option. Titration range, contraindications, and the equipm Clinical GuideCalculating the Maximum Lidocaine Dose: The Arithmetic Every Injector Should Do ColdHow to calculate a maximum lidocaine dose from weight and concentration, with worked examples — and why the number is a safety ceiling,